Oriana Miltiadous, MD

Dr. Miltiadous is investigating how the gut microbiome affects the immune system in children undergoing a cancer treatment called allogeneic hematopoietic cell transplantation (allo-HCT), which is often used for aggressive pediatric cancers like leukemia and lymphoma. While it can be life-saving, allo-HCT can also induce complications caused by immune overactivation, including graft-versus-host disease. Molecules called bile acids, produced with the help of gut microbes, help balance the immune response, reducing harmful inflammation and improving recovery. By identifying specific gut microbes and bile acids that support immune function, Dr. Miltiadous aims to reduce complications, improve survival rates, and enhance the quality of life for children receiving allo-HCT. By analyzing a cohort of over 400 patients, she seeks to uncover actionable insights that could lead to new therapies targeting the gut microbiome. Dr. Miltiadous received her MD from University of Athens Medical School, Athens.